These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 12053862)

  • 1. Clinical issues in the administration of an anti-epidermal growth factor receptor monoclonal antibody, IMC-C225.
    Hollywood E
    Semin Oncol Nurs; 2002 May; 18(2 Suppl 2):30-5. PubMed ID: 12053862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody.
    Needle MN
    Semin Oncol; 2002 Oct; 29(5 Suppl 14):55-60. PubMed ID: 12422314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer.
    Herbst RS; Kim ES; Harari PM
    Expert Opin Biol Ther; 2001 Jul; 1(4):719-32. PubMed ID: 11727507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers.
    Herbst RS; Langer CJ
    Semin Oncol; 2002 Feb; 29(1 Suppl 4):27-36. PubMed ID: 11894011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer.
    Herbst RS; Hong WK
    Semin Oncol; 2002 Oct; 29(5 Suppl 14):18-30. PubMed ID: 12422310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cetuximab: adverse event profile and recommendations for toxicity management.
    Thomas M
    Clin J Oncol Nurs; 2005 Jun; 9(3):332-8. PubMed ID: 15973844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Contribution to acneiform eruptions by epidermal growth factor receptor inhibitors].
    Bodet D; Bartralot R; Mollet J; Heras C; García-Patos V
    Actas Dermosifiliogr; 2006 Mar; 97(2):148-9. PubMed ID: 16595122
    [No Abstract]   [Full Text] [Related]  

  • 8. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225.
    Busam KJ; Capodieci P; Motzer R; Kiehn T; Phelan D; Halpern AC
    Br J Dermatol; 2001 Jun; 144(6):1169-76. PubMed ID: 11422037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation.
    Buchsbaum DJ; Bonner JA; Grizzle WE; Stackhouse MA; Carpenter M; Hicklin DJ; Bohlen P; Raisch KP
    Int J Radiat Oncol Biol Phys; 2002 Nov; 54(4):1180-93. PubMed ID: 12419447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor biology (IMC-C225).
    Kim ES; Khuri FR; Herbst RS
    Curr Opin Oncol; 2001 Nov; 13(6):506-13. PubMed ID: 11673692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Previously irradiated areas spared from skin toxicity induced by cetuximab in six patients: implications for the administration of EGFR inhibitors in previously irradiated patients.
    Bossi P; Liberatoscioli C; Bergamini C; Locati LD; Fava S; Rinaldi G; Orlandi E; Olmi P; Tagliabue E; Ménard S; Licitra L
    Ann Oncol; 2007 Mar; 18(3):601-2. PubMed ID: 17074970
    [No Abstract]   [Full Text] [Related]  

  • 12. Risk of high-grade skin rash in cancer patients treated with cetuximab--an antibody against epidermal growth factor receptor: systemic review and meta-analysis.
    Su X; Lacouture ME; Jia Y; Wu S
    Oncology; 2009; 77(2):124-33. PubMed ID: 19622903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma.
    Motzer RJ; Amato R; Todd M; Hwu WJ; Cohen R; Baselga J; Muss H; Cooper M; Yu R; Ginsberg MS; Needle M
    Invest New Drugs; 2003 Feb; 21(1):99-101. PubMed ID: 12795534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer.
    Ouwerkerk J; Boers-Doets C
    Eur J Oncol Nurs; 2010 Sep; 14(4):337-49. PubMed ID: 20580896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy.
    Pinto C; Barone CA; Girolomoni G; Russi EG; Merlano MC; Ferrari D; Maiello E; ;
    Oncologist; 2011; 16(2):228-38. PubMed ID: 21273511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
    Wong SF
    Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Manage infusion reactions from cetuximab.
    Becze E
    ONS Connect; 2008 Sep; 23(9):18-9. PubMed ID: 18807709
    [No Abstract]   [Full Text] [Related]  

  • 18. Images in clinical medicine. Cetuximab-associated acneiform eruption.
    Moss JE; Burtness B
    N Engl J Med; 2005 Nov; 353(19):e17. PubMed ID: 16282170
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147.
    Jatoi A; Green EM; Rowland KM; Sargent DJ; Alberts SR
    Oncology; 2009; 77(2):120-3. PubMed ID: 19622902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cetuximab: from bench to bedside.
    Vincenzi B; Zoccoli A; Pantano F; Venditti O; Galluzzo S
    Curr Cancer Drug Targets; 2010 Feb; 10(1):80-95. PubMed ID: 20088790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.